Oncoprotein 18 (Op18) is a major cystolic phosphoprotein conlation, thus coupling of Op18 phosphorylation to cell proliferstituent of leukemia cells. There is cumulative evidence that ation remained intact. 
Introduction
Resting normal lymphocytes were isolated from the venous blood of healthy volunteers using Ficoll-Paque according to Oncoprotein 18 (Op18), also commonly referred to as the manufacturer's protocol. Normal lymphocytes were stathmin 1 is a highly conserved 18 kDa phosphoprotein which treated with PHA (1 g/ml) for 72 h. Leukemia cells were isois expressed at low levels in mature resting G0 lymphocytes lated by the Ficoll-Paque method either from peripheral blood and undergoes rapid phosphorylation after activation of lymor bone marrow samples obtained freshly from patients. In phocytes through the T cell receptor. 2 After entry into the cell most preparations, the leukemia cells constituted more than cycle, Op18 synthesis is induced in late G1 and S and is asso-90% of the total cell count. The leukemia diagnosis was based ciated with a further increase in Op18 phosphorylation. 2 on standard morphological, cytochemical, immunological, A high diversity of Op18 molecular forms have been identand in some cases, molecular criteria. 12, 13 Patients were divified in two-dimensional electrophoretic gels (M r = 19000-ided into five groups: ANLL, T ALL, B ALL, CALLA-positive 23000; pI = 5.6-6.2). This pattern reflects, for the most part, ALL (C ALL), and CALLA negative non-T, non-B ALL (NTNB), the combined activity of intracellular kinases on the Op18 based on surface marker analysis. Specifically, the T ALL subphosphorylation state. Op18 was shown to be a good subtype was based on reactivity with T cell surface markers and strate in vitro for the cAMP-dependent protein kinase, 3, 4 absence of significant reactivity with CALLA and myeloid marcdc2, 3, 5 and MAP kinase. 6 The efforts of several groups have kers. The B ALL subtype was based on the occurrence of surled to the identification of four phosphorylated sites involving face Ig and L3 morphology. The CALLA-positive ALL subtype Ser16, Ser25, Ser38 and Ser63.
3,7-9 Most Op18 isoforms can did not include CALLA + T ALL cases. ALL was distinguished be accounted for by phosphorylation on the four distinct sites from ANLL, based on morphology, cytoreactivity and surface identifed in vitro. 3 The two major phosphorylated forms marker expression. Cases with biphenotypic marker Op18a and Op18b are predominantly phorphorylated at expression were excluded from analysis. Ser25 for Op18a, and Ser25 and Ser38 for Op18b. 8 Pronounced cell cycle-regulated phosphorylation of sites that are efficiently phosphorylated in vitro by cdc2 kinases S phase determination have provided correlative evidence for a role for Op18 in cell cycle control. Phosphorylation of Op18 is highly regulated Aliquots of cell suspensions of the various samples were during the cell cycle. During mitosis Op18 is phosphorylated stained with propidium iodide, and their DNA content was at the four sites, Ser16, Ser25, Ser 38 and Ser63. 9 determined by flow cytometry. 14, 15 The data was analyzed We initially identified Op18 as a major cytosolic constituusing the PARA 1 program. 16 ent of acute leukemia cells of different lineages. 10 Because of the strikingly high levels of Op18 in acute leukemias in which cells are arrested at an immature stage, we previously examTwo-dimensional electrophoresis and polypeptide spot ined the pattern of expression of Op18 during lymphoid quantification development. 11 We found that immature thymocytes constitutively expressed high levels of unphosphorylated Op18, Electrophoretic conditions were as previously described. 17 independent of cell cycle progression. An increase in Op18 Cells were washed twice in phosphate-buffered saline, pelphosphorylation was observed following mitogenic stimuleted in microcentrifuge tubes, and solubilized by the addition of 50 l per 5 × 10 6 cells of a standard lysis solution containing: 9 M urea, 20 ml non-ionic detergent (NP-40), 20 ml of ampholytes (pH 3.5-10), 20 ml of 2-mercaptoethanol, and deionized water. Samples of 30 l were applied immediately ALL subgroups. Op18a was highly correlated with Op18 for the entire group of leukemia samples (r = 0.68, P Ͻ 0.001), after preparation on to isoelectric focusing gels. First-dimension gels contained 50 ml of ampholytes/liter (pH 3.5-10). Isoand Op18b was highly correlated with Op18a (r = 0.68, P Ͻ 0.0001). The correlation between Op18 and Op18b was electric focusing was done at 1200 V for 16 h and 1500 V for the last 2 h. For the second dimension, an acrylamide gradient statistically significant but not as large (r = 0.30, P Ͻ 0.001). Generally this pattern of correlation was observed within each of 11.4-14 g/dl was used. In most cases, proteins were visualized using a silver staining technique. 18 For quantitative subtype of leukemia as well. There tended to be greater amounts of Op18a and Op18b as a percentage of total Op18 analysis, gels were digitized and spots were detected and quantitated as previously described.
19 Op18, Op18a and in those samples for which total Op18 was greater (r = 0.21, P = 0.01), and this correlation was positive within each leukeOp18b were identified based on their pI, characteristic location, and prior structural analysis by mass spectrometry. 8 mia subtype, although not always statistically significant. Generally the trend was that samples with a higher white count The integrated intensity of Op18, Op18a and Op18b and 20 other stably expressed reference polypeptides in the gel were had higher levels of all three forms of Op18, total Op18, as well as the percentage of the total Op18 present as the phosmeasured in units of optical density times square millimeter. The 20 reference protein spots were used to adjust the Op18, phorylated forms Op18a and Op18b. In the T ALL group in particular, Op18, Op18a, and Op18b were all significantly Op18a and Op18b integrated intensity for gel to gel variation due to any differences in gel staining or amount of protein correlated with white count (r = 0.63, 0.65 and 0.60, respectively, P Ͻ 0.01). loaded.
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Results
Relationship between Op18, Op18a and Op18b levels and the percentage of cells in S phase Differential expression of unphosphorylated Op18, and phosphorylated Op18a and Op18b in acute
Because of the involvement of Op18 in cellular proliferation, we attempted to correlate the abundance of Op18 isoforms leukemia subtypes with the percentage of leukemia cells in the S phase at the time of diagnosis. We were able to obtain measures of the The 2-D polypeptide patterns of leukemia cells from a patient with T ALL, from a patient with C ALL, and of normal and percent of cells in S phase from samples collected in parallel to those used for 2-D gel analysis in 75 cases. Eight of these PHA-treated peripheral blood lymphocytes are shown in Figure 1 . The mean integrated intensities of Op18 were samples obtained from patients at the time of relapse for which we had no previous samples, the inclusion of which (unphosphorylated), Op18a (phosphorylated), and Op18b (phosphorylated) for different subtypes of leukemia are shown does not change the overall findings substantially but does increase the sample sizes and the statistical significance of the in Table 1 , which also includes values obtained from resting lymphocytes and lymphocytes stimulated with PHA for 72 h comparisons. Patients were divided into two groups of approximately equal size based on whether the measured peras a reference. On average the total Op18 (unphosphorylated + phosphorylated) measured in the leukemia samples was cent of leukemia cells in S phase was less than or greater than 8%. The mean Op18, Op18a, and Op18b measurements for slightly higher than that for PHA-stimulated lymphocytes and much higher than total Op18 in resting lymphocytes.
these groups, as well as the same measures for C ALL and T ALL samples are shown in Table 3 . For all leukemia samples T ALL samples had significantly higher total Op18 than ANLL, C ALL and NTNB (P Ͻ 0.05 for two sample t-tests).
combined, there was significantly greater mean Op18, Op18a, and total Op18 in the subset with the higher percent Comparisons of mean unphosphorylated Op18 integrated intensity in T ALL samples to ANLL, C ALL, and NTNB S phase cells (P Ͻ 0.05). Op18b was also higher in this subset but the difference was less significant. These differences were samples gave P values of 0.06, 0.09 and 0.04, respectively. Phosphorylated Op18a levels were also higher in T ALL almost entirely due to the C ALL samples in the data set which contributed 53 of the 75 samples and gave similar results in samples in comparison to ANLL, C ALL, and NTNB, all comparisons giving P values of less than 0.05. There were relastatistical comparisons (Table 3) . tively fewer B ALL samples in the data set and comparisons between T ALL and B ALL did not yield statistically significant results.
Analysis of Op18, Op18a and Op18b levels with regard to relapse We examined the relationship between Op18 levels and subRelationship between Op18, Op18a and Op18b levels and peripheral white blood cell count (WBC) sequent relapse for the subset of 151 patients for whom follow-up was available. Mean follow-up time was 31 months, with only 15 patients followed-up for less than 12 months. To determine the extent to which the abundance of Op18 isoforms was correlated with the white cell count of the patients Table 4 gives the mean spot integrated intensities for Op18, Op18a and Op18b categorized by outcome. The data demonat the time of diagnosis, patients independent of their diagnosis, were divided into four groups: (1) WBC Ͻ5 × 10 3 ; (2) strate that for all leukemia subtypes combined, patients who later relapsed had significantly smaller unphosphorylated WBC between 5 × 10 3 and Ͻ5 × 10 4 ; (3) WBC between 5 × 10 4 and 5 × 10 5 ; (4) WBC Ͼ5 × 10 5 . Phosphorylated Op18 on average, and a significantly greater percentage of phosphorylated Op18 forms ([Op18a + Op18b]/[total Op18a and Op18b levels were correlated with white count for the entire group of samples (r = 0.26 and 0.22, respectively, Op18s]). Op18b was larger in relapsed patients, but not significantly so (P = 0.20). It is possible that such a finding could P Ͻ 0.01). Table 2 presents the mean values obtained in each of the four groups of patients categorized by white count for have been due to differences in relapse rates between different subtypes of leukemia, so we made similar comparisons for the the entire group of patients as well as for the C ALL and T
Figure 1
Representative 2-D patterns of T ALL (a), C ALL (b), resting lymphocytes (c) and PHA-stimulated lymphocytes (d). Op18 isoforms are indicated with arrows. C ALL group alone, which is the subtype with the most data and percent phosphorylated Op18 were small and paired t- (Table 4 ). The percentage of total Op18 present in the phostests gave no significant differences, suggesting that Op18 levphorylated forms (Op18a + Op18b) was still significantly els and phosphorylation patterns are maintained in leukemia greater (P = 0.02).
cells at time of relapse. There were 13 cases for which both an initial sample and a sample at the time of relapse were available for the same patient. Op18 levels for these samples are summarized in Table 5 . Differences for Op18, Op18a, Op18b, total Op18, Discussion phorylated Op18 may exert different functional properties from the phosphorylated forms. T ALL samples had significantly higher total Op18 and phosphorylated Op18a than We have previously described high levels of Op18 in acute leukemia.
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It became subsequently clear that Op18 ANLL, C ALL, and NTNB samples. These findings agree with the results of Brattsand et al. 22 Additionally, our data point to expression was also significantly higher in non-proliferating immature thymocytes relative to mature thymocytes and peria significant correlation between Op18 phosphorylation and cellular proliferation as determined by percent S phase. We pheral blood T cells. 11 Thus expression of Op18 at high level in acute leukemia is likely due to the immature phenotype of observed a significantly higher level of phosphorylated Op18a and Op18 in samples with higher percent S phase cells. These leukemia cells. In contrast to the constitutive expression of Op18 in immature cells, Op18 phophorylation occurs in results are in contrast to the findings of Roos et al, 23 in which a correlation between Op18 level and proliferation was sugresponse to signals from diverse growth regulatory pathways and there is a distinct pattern of Op18 phosphorylation during gested for lymphoma but not for leukemia cells. The difference could be attributed to the method of quantification of progression through the cell cycle, and in leukemia cells relative to immature thymocytes isolated from the Op18. We relied on 2-D gels followed by computer digitization and quantitation of individual Op18 isoforms, while thymus. 10, 11, 20, 21 In a previous study, we demonstrated, using antisense Roos et al used flow cytometry. Moreover, we examined a larger sample size (75 compared to 29). 23 oligos against Op18 mRNA, that a reduction in Op18 protein level led to a decrease in proliferation. 20 In this study, we have We also investigated the association between the level of Op18 and the leukemia burden as determined by the WBC. undertaken for the first time, quantitative analysis of each of the three major isoforms of Op18 in acute leukemia. The
For the entire group of samples, phosphorylated Op18a and Op18b correlated significantly with the WBC. Moreover, we major forms are unphosphorylated Op18 and phosphorylated Op18a and Op18b. The rationale for the study is that unphosfound that the higher the WBC, the higher the percentage of Op18 phosphorylation and the leukemia burden suggest that strategies aimed at manipulating Op18 levels and/or phosphorylation may be effective in inhibiting leukemia cell proliferation. 
